Abstract:The current study evaluated the differencein clinical characteristics, treatment strategy, trends in mortality, and medical costs according to the etiologies of CS, using data from the Korean National Health InsuranceService. There was a decreasing trend in in‐hospital mortalityand increasing trends in actual medical costs among all CS patients,irrespective of etiology. HF‐CS was associated with significantly higher risksof mortality than AMI‐CS. These results emphasize that the need for effective treatment strategies forpatients with HF‐CS. AMI, acute myocardial infarction; CS, cardiogenic shock; ICM, ischemic cardiomyopathy. Aims This study sought to examine the difference in clinical characteristics, treatment strategy, trends in mortality, and medical costs according to the aetiologies of cardiogenic shock (CS). Methods and results This was a population‐based, nationwide, cohort study from the Korean National Health Insurance Service database. All CS adults (≥18 years) were admitted to an intensive care unit from January 2010 to December 2020. The primary outcome was in‐hospital mortality. The secondary outcomes were cardiac replacement therapy (left ventricular assisted device implantation or heart transplantation), all‐cause mortality, ischaemic stroke, rehospitalization for heart failure (HF) during follow‐up, and actual in‐hospital medical costs. Among 136 092 individuals with CS, 48 704 (29.7%) cases were due to acute myocardial infarction‐related CS (AMI‐CS), and the remaining 87 388 (71.3%) were due to HF‐CS (ischaemic cardiomyopathy [ICM] vs. non‐ICM, 49 504 [56.6%] vs. 37 884 [45.4%]). Patients with HF‐CS were older, less likely to be male, and less likely to receive mechanical circulatory support, compared to those with AMI‐CS. During the 10‐year study period, the in‐hospital mortality rate decreased, and actual medical costs tended to increase, regardless of CS aetiology. Compared with AMI‐CS, HF‐CS was associated with higher risks of in‐hospital mortality (40.3% vs. 28.5%; adjusted odds ratio [OR] 1.47, 95% confidence interval [CI] 1.43–1.52), cardiac replacement therapy (adjusted OR 1.65, 95% CI 1.16–2.34), as well as follow‐up mortality after successful discharge (19.3% vs. 8.5%; adjusted‐hazard ratio 1.54, 95% CI 1.48–1.59). HF‐CS had lower medical costs than AMI‐CS (adjusted ratio 0.79, 95% CI 0.79–0.80). Conclusions With medical advances during the past 10 years, the mortality of CS has decreased significantly, but the mortality of HF‐CS remains high. The findings highlight the need for effective treatment strategies for patients with HF‐CS.

Characteristics of High-Performing Hospitals in Cardiogenic Shock Following Acute Myocardial Infarction

Trends in Cardiogenic Shock-Related Mortality in Patients with Acute Myocardial Infarction in the United States, 1999 to 2019.

Abstract 12617: Predictors of Mortality in African Americans Requiring Intra-Aortic Balloon Pump for Cardiogenic Shock Following Acute Myocardial Infarction

The processes of care and long-term mortality of acute myocardial infarction with cardiogenic shock survivors: A nationwide cohort study

US trends of in-hospital morbidity and mortality for acute myocardial infarctions complicated by cardiogenic shock

Factors Associated with the Prognosis of Patients with Acute Myocardial Infarction and Cardiogenic Shock

Predictors of Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock despite Intra-Aortic Balloon Pump: Opportunities for Advanced Mechanical Circulatory Support in Asia

Resource Utilization and Costs Associated With Cardiogenic Shock Complicating Myocardial Infarction: A Population-Based Cohort Study

Trends and outcomes of different mechanical circulatory support modalities for acute myocardial infarction associated cardiogenic shock in patients undergoing early revascularization

American Heart Association Cardiogenic Shock Registry: Design and Implementation

Comparative analysis of cardiogenic shock outcomes in acute myocardial infarction with polyvascular disease

Management and Outcomes of Cardiogenic Shock in Cardiac ICUs with Versus Without Shock Teams.

In‐hospital and long‐term outcomes of cardiogenic shock complicating myocardial infarction versus heart failure

Early vs. Delayed Mechanical Circulatory Support in Patients with Acute Myocardial Infarction and Cardiogenic Shock

Sex Differences in Characteristics, Resource Utilization, and Outcomes of Cardiogenic Shock: Data From the Critical Care Cardiology Trials Network (CCCTN) Registry

Sex Differences in Management, Time to Intervention, and In-Hospital Mortality of Acute Myocardial Infarction and Non-Myocardial Infarction Related Cardiogenic Shock

Impact of Right Ventricular Dysfunction on Outcomes in Acute Myocardial Infarction and Cardiogenic Shock: Insights from the National Cardiogenic Shock Initiative

Characteristics and outcome in cardiogenic shock according to vascular access site for percutaneous coronary intervention

A Risk Stratification Scheme for In-Hospital Cardiogenic Shock in Patients With Acute Myocardial Infarction

Factors associated with 30-day mortality in patients receiving mechanical circulatory support for cardiogenic shock

Abstract 18298: 10-Year Trends of In-Hospital Outcomes of Patients That Underwent Percutaneous Coronary Intervention for Cardiogenic Shock Complicating Acute Coronary Syndrome